Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter, Phase 3 Clinical Study to Investigate the Efficacy and Safety of 50 mg Daridorexant in Adult and Elderly Chinese Patients With Insomnia Disorder.

NCT06010693 is registered in ClinicalTrials.gov with Jiangsu Simcere Pharmaceutical Co., Ltd. as lead sponsor.

NCT NCT06010693
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06010693 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter, Phase 3 Clinical Study to Investigate the Efficacy and Safety of 50 mg Daridorexant in Adult and Elderly Chinese Patients With Insomnia Disorder.
Lead sponsor
Jiangsu Simcere Pharmaceutical Co., Ltd.
Phase
Phase 3
Overall status
Completed
Start date
August 28, 2023
Completion date
May 10, 2024
Enrollment
206 (actual)
Sites
33

Conditions

As the registry lists them; a condition with its own page is linked.

insomnia disorder